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Tibolone is a STEAR (Selective tissue estrogenic
activity regulator) (1). It is a synthetic steroid with tissue
selectivity that has progestogenic, some androgenic as
well as estrogenic effects. It has been used as an
alternative to estrogen replacement therapy in several
European countries for almost 2 decades, primarily for
the prevention of postmenopausal osteoporosis and
treatment of climacteric symptoms.
Mechanism of action (2) : Tibolone itself has no
biological activity; its effects are the results of the activity
of its metabolites on various tissues. After administration,
tibolone is quickly metabolized into 3a-hydroxytibolone
(3 ß OH-tibolone) and 3 ß-OH-tibolone compounds,
which are also present in an inactive, sulfated form. A
third compound, the ?4- isomer, is formed from tibolone
directly or from the 3 ß -OH-metabolites.  Tibolone has
estrogenic effects on bone and vaginal tissue. In
endometrial tissue the ?4-isomer functions as a
progestagen, whereas in the brain and liver it has
androgenic effects. In breast tissue, the main actions of
tibolone are strong inhibition of sulfatase activity and
weak inhibition of 17 a -hydroxysteroid dehydrogenase
activity, which result in blocking the conversion of
estrone sulfate to E2. Tibolone actions are as follows :
Climacteric Symptoms : Menopause-associated
symptoms impair quality of life for many women. More
than 75% of postmenopausal women experience hot
flushes, sweating, insomnia, headache, fatigue, changes
in mood and libido. Tibolone has been shown to be
effective in the treatment of vasomotor symptoms and
provides positive effects on sexual function (3, 4). Tibolone
may improve mood, libido and somatic symptoms in
surgically menopausal women to a greater extent than
estrogen therapy alone (5).
Sexual Function : Tibolone has been shown to increase
libido and frequency of sexual activities , mainly by its
androgenic activity (6).Clitoral circulation in
postmenopausal women reporting female sexual
dysfunction (FSD) is significantly increased under
tibolone in comparison with Estrogen progestron therapy
with a better improvement of sexual function (7).  In the
first trial by Nevinny-Stickel (8), there was no significant
improvement in regard to libido in women taking
tibolone. On the contrary, the recent double blind and
placebo-controlled trial by Laan (9) has shown that
treatment with tibolone significantly improved the
physiological aspects of sexual function in
postmenopausal women, such as vaginal blood flow,
vaginal lubrication, and subjective measures, such as
sexual desire and arousability, but there was no difference
in the frequency of sexual intercourse, nonpenetrative
sexual activity, or initiation and rejection of sexual
activity between  women who were taking tibolone vs.
those receiving placebo (9).
Hot Flushes and Sweating : Compared with placebo,
most RCTs reported a significant reduction in hot flushes
and sweating in women taking tibolone .When the effects
of tibolone on hot flushes were compared with the effects
of other hormones, a similar reduction of hot flushes was
seen with both therapies. Tibolone and 17beta- oestradiol
/dydrogesterone oral tablets were effective and safe to
treat short- and intermediate-term symptoms in Middle-
Eastern postmenopausal women, within 6 months, and
thus, the use of HRT to relieve menopausal symptoms is
highly recommended, at least in this region (4). Tibolone
induces a significant decrease in the frequency and
intensity of climacteric symptoms at a dose levels of 1.25
mg and higher. However, a daily dose of 2.5 mg is the
optimal dose (10)
Mood : In one small trial of young women who had
undergone oophorectomy and hysterectomy, Crona et al.
(11) found that tibolone and E2 valerate reduced hot
flushes and improved mood to a similar degree. In another
trial, Genazzani (12) found that the relief of hot flushesJK SCIENCE
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from the second month of treatment was associated with
improvement of both mood and insomnia. Tibolone
increases  the concentration of endorphins which might
contribute to the improved mood in postmenopausal
women  A Continuous combined hormone replacement
regimens, CEE + MPA and tibolone, have superior long-
term effects on mood scores in menopause and should
be considered during the decision process for use of HRT
due to menopausal symptoms (13).
Vaginal Bleeding and Endometrium : In the
endometrium, tibolone is transformed into the ?4- isomer
by 3ß-hydroxysteroid dehydrogenase isomerase. This
metabolite does not have estrogenic activity, but has
intrinsic progestagenic activity; therefore, it does not
stimulate the endometrial tissue. Thus, therapy with
tibolone may not require the addition of progestagen to
protect the endometrium (14). More over, there has been
no evidence that tibolone can have adverse effects on
the disease free survival and overall survival of
endometrial cancer patients. So, tibolone could be used
in these patients (15). However, endometrial effects of
tibolone need to be assessed in larger trials. A thorough
investigation in patients presenting with vaginal bleeding
while on tibolone should be carried out, despite the
absence of endometrial thickness by sonogram (14)
Lipids : Tibolone decreases triglyceride levels much
more than transdermal estradiol. However, HDL
cholesterol is decreased by tibolone and increased by
transdermal estradiol. Tibolone had a more marked
decreasing effect in postmenopausal women who had
higher initial triglyceride levels (16). It seems that the
beneficial effect of tibolone on the cardiovascular system
might be greater in women with a high level of
triglycerides whereas hypercholesterolemic women
benefit more from the cholesterol-lowering effect of
estrogen replacement therapy/HRT (17)
In another study use of tibolone has been suggested
to decrease the concentration of the total cholesterol,
triglicerides, HDL cholesterol, without a significant
decrease of LDL cholesterol. Also, the use of tibolone
does not have any significant effect on the concentrations
of antitrombin III, fibrinogen and C-reactive proteine
(18). However, the androgenic effects of tibolone can
increase fibrinolytic activities (19) which can be
cardioprotective.
Breast Cancer :  There is clear evidence that HRT
causes breast cancer and the challenge for the physician
is to control the menopausal symptoms using HRT or
alternatives while at the same time limiting the risks
associated with this treatment. Tibolone, a
gonadomemetic agent which has been used to control
menopausal symptoms, appears to have less direct effects
on the breast (20). In breast cells, tibolone slows down
the proliferation rate as well as increases differentiation
and apoptosis. This has led to the view that tibolone might
reduce breast cancer risk.(21). Colacurci showed that 1
yr of tibolone treatment did not affect breast density in
postmenopausal women with normal breast tissue
compared with a control group and a hormonal
replacement therapy group (22). Hammar (23) reported
that postmenopausal women taking tibolone experienced
breast tenderness significantly less frequently than those
who were taking E2/NETA.
Epithelial Ovarian Cancer : There is no evidence that
tibolone can have detrimental effects on the progression
free survival and overall survival of epithelial ovarian cancer
patients. So, tibolone can be used in these patients (24).
Postmenopausal Osteoporosis (25,26) : Tibolone
prevents bone loss in a similar way to estrogens Loss of
bone in the spine and proximal hip can be prevented with
tibolone 2.5 mg/day in early and late postmenopausal
women. Many studies show increase in bone mineral
density at other sites like phalanges and hip. Tibolone is
effective, even at lower doses, in preventing a decrease
in spine and femur BMD in early postmenopausal
women(25). Tibolone might be such an agent. However,
so far, no fracture data are available; all existing studies
have shown a positive action of tibolone on bone mineral
density. No study has been tailored to study the
antifracture efficacy. The Long Term Intervention on
Fractures with Tibolone (LIFT) study has been started
with the aim at filling the gap between bone mineral
density maintenance and bone fracture prevention(26).
Current recommendation : An international
multidisciplinary panel of experts  met at  the 4th
Amsterdam Menopause Symposium in October 2004 and
the  consensus was that tibolone is a valuable treatment
option for women with climacteric complaints (27). It
has positive effects on sexual well-being and mood, and
improves vaginal atrophy and urogenital symptoms.
Absolute numbers of women at increased risk for breast
cancer are estimated to be low or absent with both
tibolone and ET, and the risk with tibolone should be
significantly lower than that with EPT. Tibolone might
therefore be preferable to EPT in certain women who
have not been hysterectomised (27).